Revenues driven by recent contracts for the most advanced life saving diagnostics will expand 150 times in the next 24 months. And that is just the beginning!
Millennium Healthcare (MHCC) recently announced newly SIGNED contracts with ACO’s IPA’s and MSO’s to provide exclusive, state-of-the-art, non-invasive cardiovascular and cancer diagnostics to 1,300 locations that will escalate Millennium’s current revenues of $2 million per year to over $300 million per year.
Cardiovascular and cancer diagnostics rolling out to physician’s offices this year.
Revenues will begin rapid growth by year end.
Market size for Millennium Diagnostics is 35,000 primary care offices. The first 1,300 recently contracted with Millennium and the rest are standing in line to sign up with Millennium because:
§ Millenniums program increases physician’s revenues dramatically
§ Millennium’s diagnostics are fully paid by Medicare and are free to patients
§ Millennium’s diagnostics appeal to patients because they are life-saving, fast, painless and highly accurate
§ Millennium’s diagnostics are exclusive from Millennium only
§ The physician pays no up front capital costs
Millennium’s market cap is under $40 million today and shares are selling at under $1.00.
What will this growth do to the price of MHCC shares?
Millennium HealthCare is well positioned for explosive growth that is rarely seen.
Sentiment: Strong Buy
At one point Insulet could have been purchased for $4+/share. Now it is north of $40+/share and still no buy-out. My guess is either management is not interested in being purchased or other larger companies do not see an acceptable return at the current valuation. In addition for companies that should be interested Medtronic, J&J etc. this technology may be disruptive to existing income streams they are trying to protect. My opinion is the Podd applications will eventually go well beyond Insulin and become the norm for most continuous injectables in hospitals, home care, etc. Should reduce the number of nurse visits and instead drug injections may be made remotely from nursing stations or even the web based upon automated vital signs / patient feedback. Less nursing care equals lower healthcare cost. So Insulet's only limitations should be the cost of the Podds (going down) and the volume (going up) they can manufacture plus regulatory approvals.
Sentiment: Strong Buy
any sensible information, on whether this co will be taken over by a larger entity, would be greatly appreciated. As far as I know they have the only tubing less insulin pump currently on the market.
I just spoke to a very nice customer service rep because my son called 9 DAYS AGO about 3 bad pods that he needed replaced and they apparently just shipped yesterday. Based on our previous shipping wait times with Insulet, he's got a loooong time to wait yet. Eight days to respond to a request for replacement pods is unacceptable. When he switched to the new system, the stated shipping time for the new PDM was 12 days. He did not receive it for 2 days after the originally stated ridiculous time. As I explained to the rep, it is as if this company does not understand the population it is dealing with. Nor its own product. There are ALWAYS pod failures. Some of them are alarming on the front step in the shipping box. They need to bake in a few extras with every order. This need not be an insurance issue, it should be company policy. Until they make a perfect no-fail pod, be proactive, for the love of Pete. Very frustrated right now. This equipment isn't an option, it is a necessity. It needs to be treated as such by the company that produces it.
I disagree that moving to the new Pod is difficult. My daughter has been a user for many years and is 15 years old and di the entire swap by herself. We have never had a problem with customer service. They have been responsive the few times we have needed to call.
Sentiment: Strong Buy
Dido on the customer service issue. My son has run out of pods and we can not get through to order more. Even the reps can not get product.
As a long-time (long) shareholder, and user of Insulet products, it is sickening to see how their current customer service situation is affecting the company. Though they have a great product, they are not able to take sales or reorders from customers because they can't answer their phones. Yes, switching costs are high for their existing customers but if new customers can't place orders they are certainly going to suffer. Without drastic improvements to their sales and customer service processes Insulet is going to start to see very disappointing sales numbers in the near future.
your answer might be here
anyone know what's going on? I hear some sellside is writing about the lawsuit with medtronic, but that's old news from back in september, and those patent cases take years and years to play out.